CD8A and neoplasm: The addition of NY_1xCD3_v3 induced a dose-dependent increase in the activation markers CD25 (Figures 5A and 5B) and CD69 (Figure 5C) on CD8+ T cells in the presence of all HLA-A∗0201/NY-ESO1157-165 (9C)-positive tumor cell lines, but not in antigen-negative cells.